Gastrointestinal stromal tumor

被引:97
作者
Zhao, Xiaohui [1 ]
Yue, Changjun [2 ]
机构
[1] Univ Calif Irvine, Sch Med, Dept Pathol & Lab Med, Irvine, CA 92697 USA
[2] LabCorp, Integrated Oncol, Irvine, CA 92604 USA
关键词
Gastrointestinal stromal tumor; GIST; KIT mutation; imatinib;
D O I
10.3978/j.issn.2078-6891.2012.031
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gastrointestinal stromal tumor has received a lot of attention over the last 10 years due to its unique biologic behavior, clinicopathological features, molecular mechanisms, and treatment implications. GIST is the most common mesenchymal neoplasm in the gastrointestinal tract and has emerged from a poorly understood and treatment resistant neoplasm to a well-defined tumor entity since the discovery of particular molecular abnormalities, KIT and PDGFRA gene mutations. The understanding of GIST biology at the molecular level promised the development of novel treatment modalities. Diagnosis of GIST depends on the integrity of histology, immunohistochemistry and molecular analysis. The risk assessment of the tumor behavior relies heavily on pathological evaluation and significantly impacts clinical management. In this review, historic review, epidemiology, pathogenesis and genetics, diagnosis, role of molecular analysis, prognostic factor and treatment strategies have been discussed.
引用
收藏
页码:189 / 208
页数:20
相关论文
共 193 条
[41]   KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours [J].
Debiec-Rychter, Maria ;
Sciot, Raf ;
Le Cesne, Axel ;
Schlemmer, Marcus ;
Hohenberger, Peter ;
van Oosterom, Allan T. ;
Blay, Jean-Yves ;
Leyvraz, Serge ;
Stul, Michel ;
Casali, Paolo G. ;
Zalcberg, John ;
Verweij, Jaap ;
Van Glabbeke, Martine ;
Hagemeijer, Anne ;
Judson, Ian .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (08) :1093-1103
[42]   Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST) [J].
DeMatteo, Ronald P. ;
Gold, Jason S. ;
Saran, Lisa ;
Goenen, Mithat ;
Liau, Kui Hin ;
Maki, Robert G. ;
Singer, Samuel ;
Besmer, Peter ;
Brennan, Murray F. ;
Antonescu, Cristina R. .
CANCER, 2008, 112 (03) :608-615
[43]   Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial [J].
DeMatteo, Ronald P. ;
Ballman, Karla V. ;
Antonescu, Cristina R. ;
Maki, Robert G. ;
Pisters, Peter W. T. ;
Demetri, George D. ;
Blackstein, Martin E. ;
Blanke, Charles D. ;
von Mehren, Margaret ;
Brennan, Murray F. ;
Patel, Shreyaskumar ;
McCarter, Martin D. ;
Polikoff, Jonathan A. ;
Tan, Benjamin R. ;
Owzar, Kouros .
LANCET, 2009, 373 (9669) :1097-1104
[44]   Two hundred gastrointestinal stromal tumors - Recurrence patterns and prognostic factors for survival [J].
DeMatteo, RP ;
Lewis, JJ ;
Leung, D ;
Mudan, SS ;
Woodruff, JM ;
Brennan, MF .
ANNALS OF SURGERY, 2000, 231 (01) :51-58
[45]   Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].
Demetri, GD ;
von Mehren, M ;
Blanke, CD ;
Van den Abbeele, AD ;
Eisenberg, B ;
Roberts, PJ ;
Heinrich, MC ;
Tuveson, DA ;
Singer, S ;
Janicek, M ;
Fletcher, JA ;
Silverman, SG ;
Silberman, SL ;
Capdeville, R ;
Kiese, B ;
Peng, B ;
Dimitrijevic, S ;
Druker, BJ ;
Corless, C ;
Fletcher, CDM ;
Joensuu, H .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480
[46]  
Demetri George D, 2007, J Natl Compr Canc Netw, V5 Suppl 2, pS1
[47]   Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial [J].
Demetri, George D. ;
van Oosterom, Allan T. ;
Garrett, Christopher R. ;
Blackstein, Martin E. ;
Shah, Manisha H. ;
Verweij, Jaap ;
McArthur, Grant ;
Judson, Ian R. ;
Heinrich, Michael C. ;
Morgan, Jeffrey A. ;
Desai, Jayesh ;
D Fletcher, Christopher ;
George, Suzanne ;
Bello, Carlo L. ;
Huang, Xin ;
Baum, Charles M. ;
Casali, Paolo G. .
LANCET, 2006, 368 (9544) :1329-1338
[48]   Soft Tissue Sarcoma [J].
Demetri, George D. ;
Antonia, Scott ;
Benjamin, Robert S. ;
Bui, Marilyn M. ;
Casper, Ephraim S. ;
Conrad, Ernest U., III ;
DeLaney, Thomas F. ;
Ganjoo, Kristen N. ;
Heslin, Martin J. ;
Hutchinson, Raymond J. ;
Kane, John M., III ;
Letson, G. Douglas ;
McGarry, Sean V. ;
O'Donnell, Richard J. ;
Paz, I. Benjamin ;
Pfeifer, John D. ;
Pollock, Raphael E. ;
Randall, R. Lor ;
Riedel, Richard F. ;
Schupak, Karen D. ;
Schwartz, Herbert S. ;
Thornton, Katherine ;
von Mehren, Margaret ;
Wayne, Jeffrey .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2010, 8 (06) :630-674
[49]   Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors [J].
Desai, Jayesh ;
Yassa, Leila ;
Marqusee, Ellen ;
George, Suzanne ;
Frates, Mary C. ;
Chen, Ming Hui ;
Morgan, Jeffrey A. ;
Dychter, Samuel S. ;
Larsen, P. Reed ;
Demetri, George D. ;
Alexander, Erik K. .
ANNALS OF INTERNAL MEDICINE, 2006, 145 (09) :660-664
[50]   Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation [J].
Dewaele, Barbara ;
Wasag, Bartosz ;
Cools, Jan ;
Sciot, Raf ;
Prenen, Hans ;
Vandenberghe, Peter ;
Wozniak, Agnieszka ;
Schoffski, Patrick ;
Marynen, Peter ;
Debiec-Rychter, Maria .
CLINICAL CANCER RESEARCH, 2008, 14 (18) :5749-5758